277 related articles for article (PubMed ID: 14749122)
41. A macrophage-dominant PI3K isoform controls hypoxia-induced HIF1α and HIF2α stability and tumor growth, angiogenesis, and metastasis.
Joshi S; Singh AR; Zulcic M; Durden DL
Mol Cancer Res; 2014 Oct; 12(10):1520-31. PubMed ID: 25103499
[TBL] [Abstract][Full Text] [Related]
42. Imaging tumor angiogenesis.
Red-Horse K; Ferrara N
J Clin Invest; 2006 Oct; 116(10):2585-7. PubMed ID: 17016553
[TBL] [Abstract][Full Text] [Related]
43. Synopsis of angiogenesis inhibitors in oncology.
Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
[TBL] [Abstract][Full Text] [Related]
44. Hypoxia-regulated angiogenic inhibitors.
Messmer-Blust A; An X; Li J
Trends Cardiovasc Med; 2009 Nov; 19(8):252-6. PubMed ID: 20447566
[TBL] [Abstract][Full Text] [Related]
45. Opportunities and challenges in tumor angiogenesis research: back and forth between bench and bed.
Qin L; Bromberg-White JL; Qian CN
Adv Cancer Res; 2012; 113():191-239. PubMed ID: 22429856
[TBL] [Abstract][Full Text] [Related]
46. Tumor angiogenesis and therapy.
Cao Y
Biomed Pharmacother; 2005 Oct; 59 Suppl 2():S340-3. PubMed ID: 16507405
[TBL] [Abstract][Full Text] [Related]
47. Beyond Angiogenesis: Exploiting Angiocrine Factors to Restrict Tumor Progression and Metastasis.
Singhal M; Augustin HG
Cancer Res; 2020 Feb; 80(4):659-662. PubMed ID: 31831463
[TBL] [Abstract][Full Text] [Related]
48. Melatonin Regulates Angiogenic Factors under Hypoxia in Breast Cancer Cell Lines.
Jardim-Perassi BV; Lourenço MR; Doho GM; Grígolo IH; Gelaleti GB; Ferreira LC; Borin TF; Moschetta MG; Pires de Campos Zuccari DA
Anticancer Agents Med Chem; 2016; 16(3):347-58. PubMed ID: 25963143
[TBL] [Abstract][Full Text] [Related]
49. UCN-01, a protein kinase C inhibitor, inhibits endothelial cell proliferation and angiogenic hypoxic response.
Kruger EA; Blagosklonny MV; Dixon SC; Figg WD
Invasion Metastasis; 1998-1999; 18(4):209-18. PubMed ID: 10640907
[TBL] [Abstract][Full Text] [Related]
50. NNC 55-0396, a T-type Ca2+ channel inhibitor, inhibits angiogenesis via suppression of hypoxia-inducible factor-1α signal transduction.
Kim KH; Kim D; Park JY; Jung HJ; Cho YH; Kim HK; Han J; Choi KY; Kwon HJ
J Mol Med (Berl); 2015 May; 93(5):499-509. PubMed ID: 25471482
[TBL] [Abstract][Full Text] [Related]
51. [Rationale of antiangiogenic therapy].
Tímár J; Paku S; Tóvári J; Döme B
Magy Onkol; 2006; 50(2):141-51. PubMed ID: 16888678
[TBL] [Abstract][Full Text] [Related]
52. Pathophysiology of tumor neovascularization.
Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ishikura H
Vasc Health Risk Manag; 2005; 1(4):277-90. PubMed ID: 17315600
[TBL] [Abstract][Full Text] [Related]
53. Competing pathways of iron chelation: angiogenesis or anti-tumor activity: targeting different molecules to induce specific effects.
Le NT; Richardson DR
Int J Cancer; 2004 Jun; 110(3):468-9. PubMed ID: 15095318
[No Abstract] [Full Text] [Related]
54. Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models.
Harris EM; Strope JD; Beedie SL; Huang PA; Goey AKL; Cook KM; Schofield CJ; Chau CH; Cadelis MM; Copp BR; Gustafson KR; Figg WD
Mar Drugs; 2018 Jul; 16(7):. PubMed ID: 30029505
[TBL] [Abstract][Full Text] [Related]
55. Angiogenesis and Metabolism: Entwined for Therapy Resistance.
Jiménez-Valerio G; Casanovas O
Trends Cancer; 2017 Jan; 3(1):10-18. PubMed ID: 28718423
[TBL] [Abstract][Full Text] [Related]
56. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
[TBL] [Abstract][Full Text] [Related]
57. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited.
Loges S; Mazzone M; Hohensinner P; Carmeliet P
Cancer Cell; 2009 Mar; 15(3):167-70. PubMed ID: 19249675
[TBL] [Abstract][Full Text] [Related]
58. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
59. Hypoxia-inducible factor-1alpha is associated with angiogenesis, and expression of bFGF, PDGF-BB, and EGFR in invasive breast cancer.
Bos R; van Diest PJ; de Jong JS; van der Groep P; van der Valk P; van der Wall E
Histopathology; 2005 Jan; 46(1):31-6. PubMed ID: 15656883
[TBL] [Abstract][Full Text] [Related]
60. Vesicular trafficking mechanisms in endothelial cells as modulators of the tumor vasculature and targets of antiangiogenic therapies.
Maes H; Olmeda D; Soengas MS; Agostinis P
FEBS J; 2016 Jan; 283(1):25-38. PubMed ID: 26443003
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
